The European Commission has published a Temporary Framework Communication to provide guidance to companies that are cooperating to ensure the supply and distribution of essential products – including medicines and medical...more
The life sciences industry is facing unprecedented demands due to COVID-19. From front line carers to researchers and scientists, significant efforts are being put towards caring for those suffering from COVID-19 and...more
On 30 January 2020, the Court of Justice of the European Union (CJEU) issued its decision on a request for preliminary ruling submitted by the UK Competition Appeal Tribunal (CAT) in a case concerning the long-standing...more
2/5/2020
/ Abuse of Dominance ,
Advocate General ,
Anti-Competitive ,
Anticompetitive Behavior ,
Competition ,
Court of Justice of the European Union (CJEU) ,
Drug Distribution ,
EU ,
Generic Drugs ,
GlaxoSmithKline ,
Life Sciences ,
Manufacturer Liability ,
Patent Validity ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Research and Development ,
Settlement Agreements ,
UK ,
UK Competition and Markets Authority (CMA) ,
UK Competition Appeal Tribunal (CAT)
18 April 2019 Almost one and a half years after the launch of the sector inquiry, the French Competition Authority ("FCA") has released its conclusions on the functioning of competition in the pharmaceutical sector....more
4/23/2019
/ Competition ,
EU ,
France ,
French Competition Authority ,
Life Sciences ,
Medical Devices ,
Over-the-Counter Sales ,
Personal Care Products ,
Pharmaceutical Distribution ,
Pharmaceutical Industry ,
Prescription Drugs
The French Competition Authority ("FCA") found that Sanicorse, a monopoly provider of services to hospitals in Corsica, abused its dominant position by having imposed significant, sudden and unjustified price increases upon...more